BANZATO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.402
AS - Asia 1.795
EU - Europa 986
AF - Africa 432
SA - Sud America 401
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 23
Totale 8.073
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.219
SG - Singapore 622
CN - Cina 431
BR - Brasile 263
HK - Hong Kong 176
VN - Vietnam 162
DE - Germania 125
IT - Italia 113
FI - Finlandia 93
SE - Svezia 64
NL - Olanda 63
GB - Regno Unito 55
RU - Federazione Russa 50
PL - Polonia 43
FR - Francia 36
AR - Argentina 35
UA - Ucraina 33
CI - Costa d'Avorio 28
TR - Turchia 26
IN - India 25
JP - Giappone 23
KR - Corea 23
CA - Canada 22
EC - Ecuador 22
MA - Marocco 22
AT - Austria 20
BE - Belgio 18
MW - Malawi 18
GA - Gabon 17
ZA - Sudafrica 17
AL - Albania 16
CO - Colombia 16
GR - Grecia 16
IQ - Iraq 16
SA - Arabia Saudita 16
TN - Tunisia 16
TZ - Tanzania 16
AO - Angola 15
VE - Venezuela 15
IE - Irlanda 14
JM - Giamaica 14
MX - Messico 14
NP - Nepal 14
PE - Perù 14
RO - Romania 14
UZ - Uzbekistan 14
AE - Emirati Arabi Uniti 13
AM - Armenia 13
BS - Bahamas 13
GH - Ghana 13
ID - Indonesia 13
ML - Mali 13
MR - Mauritania 13
RS - Serbia 13
BG - Bulgaria 12
CW - ???statistics.table.value.countryCode.CW??? 12
HN - Honduras 12
HU - Ungheria 12
LA - Repubblica Popolare Democratica del Laos 12
LV - Lettonia 12
PT - Portogallo 12
SI - Slovenia 12
CM - Camerun 11
CU - Cuba 11
CZ - Repubblica Ceca 11
DJ - Gibuti 11
DK - Danimarca 11
EG - Egitto 11
GN - Guinea 11
KG - Kirghizistan 11
KZ - Kazakistan 11
LY - Libia 11
MD - Moldavia 11
ME - Montenegro 11
MY - Malesia 11
PY - Paraguay 11
SD - Sudan 11
SO - Somalia 11
TJ - Tagikistan 11
TW - Taiwan 11
YE - Yemen 11
ZW - Zimbabwe 11
BJ - Benin 10
HR - Croazia 10
IR - Iran 10
IS - Islanda 10
LB - Libano 10
NO - Norvegia 10
NZ - Nuova Zelanda 10
PA - Panama 10
TT - Trinidad e Tobago 10
YT - Mayotte 10
AZ - Azerbaigian 9
BW - Botswana 9
BY - Bielorussia 9
CR - Costa Rica 9
DZ - Algeria 9
ES - Italia 9
KE - Kenya 9
MN - Mongolia 9
Totale 7.696
Salva come PNG Salva come JPEG
Città #
Fairfield 635
Ashburn 474
Chandler 361
Singapore 358
Woodbridge 351
Houston 327
Ann Arbor 260
Seattle 220
Cambridge 219
Wilmington 187
Hong Kong 159
Beijing 145
Jacksonville 90
Boardman 79
San Diego 77
Dong Ket 75
Princeton 75
Santa Clara 53
Roxbury 44
Nanjing 41
Medford 40
Des Moines 39
Los Angeles 39
Helsinki 37
Munich 36
Ho Chi Minh City 34
New York 32
Bytom 28
Abidjan 27
Padova 23
Frankfurt am Main 19
Libreville 17
Nanchang 17
Guangzhou 16
Luanda 15
Tokyo 15
Dar es Salaam 14
Shenyang 14
São Paulo 14
Bamako 13
Belo Horizonte 13
Chicago 13
Hanoi 13
Hebei 13
London 13
Nassau 13
Seoul 13
Dublin 12
Kingston 12
Nouakchott 12
Tashkent 12
Vienna 12
Conakry 11
Dallas 11
Harare 11
Vientiane 11
Willemstad 11
Yerevan 11
Bishkek 10
Hefei 10
Lilongwe 10
Milan 10
Podgorica 10
Redondo Beach 10
Tripoli 10
Accra 9
Baku 9
Cotonou 9
Djibouti 9
Dushanbe 9
Havana 9
Kigali 9
Lima 9
Minsk 9
Montreal 9
Nuremberg 9
Panama City 9
San José 9
Amman 8
Athens 8
Brooklyn 8
Brussels 8
Buffalo 8
Casablanca 8
Dakar 8
Guayaquil 8
Istanbul 8
Kingstown 8
Nairobi 8
Phnom Penh 8
Sofia 8
Ulan Bator 8
Warsaw 8
Addis Ababa 7
Blantyre 7
Boston 7
Bucharest 7
Gaborone 7
Johannesburg 7
Khartoum 7
Totale 5.292
Salva come PNG Salva come JPEG
Nome #
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. 242
(188)Rhenium-induced cell death and apoptosis in a panel of tumor cell lines 235
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 213
Diagnosis and therapy of antiphospholipid syndrome 204
Laboratory testing for antiphospholipid syndrome 202
Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate 201
APS - Diagnostics and challenges for the future 198
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 197
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 184
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 184
Bioavailability of Tc-99m-Ha-paclitaxel complex [Tc-99m-ONCOFID-P] in mice using four different administration routes 183
A paclitaxel-hyaluronan bioconjugate exerts a high in vivo therapeutic activity against ovarian cancer 182
A YAP camera for the biodistribution of Re-188 conjugated with Hyaluronic-Acid in "in vivo" systems 180
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 179
Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT) 178
Biokinetic and dosimetric studies of Re-188-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma 176
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 171
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial 170
The Paradox of the Lupus Anticoagulant: History and Perspectives 166
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. 164
Antiphospholipid syndrome: critical analysis of the diagnostic path 163
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer 162
Interpretation of laboratory data and need for reference laboratories. 161
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 160
Correct laboratory approach to APS diagnosis and monitoring 157
Laboratory Diagnostics of Antiphospholipid Syndrome 155
The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis 150
β2-Glycoprotein I Binds to Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 149
Novel types of carborane-carrier hyaluronan derivatives via "click chemistry". 147
Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy 147
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. 143
Detection of lupus anticoagulant in the era of direct oral anticoagulants 141
Hydrosoluble, Metabolically Fragile Bioconjugates by Coupling Tetrabutylammonium Hyaluronan with 2′ Paclitaxel-4-Bromobutyrate: Synthesis and Antitumor Properties 140
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 135
Secondary prevention in thrombotic antiphospholipid syndrome. 134
Radiopharmacokinetic and dosimetric studies of Re-188-HA: comparison with Re-188-HDD/lipiodol 133
Clinical Relevance of β2-Glycoprotein-I Plasma Levels in Antiphospholipid Syndrome (APS) 133
Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability 123
The role of platelets in antiphospholipid syndrome 123
PN2S-PEG-BIOMOLECULE DERIVATIVES LABELED WITH TECHNETIUM-99m IN ABSENCE OF AN EXTERNAL REDUCING AGENT 120
Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines. 117
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 114
Chemical Synthesis and Characterization of Wild-type and Biotinylated N-terminal Domain 1-64 of Beta2-glycoprotein I 112
What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? 112
Beta 2 glycoprotein I selectively inhibits the procoagulant function of thrombin: a novel physiologic anticoagulant mechanism in haemostasis 111
A mouse model of liver metastasis 111
Preliminary data on the evaluation of Rhenium-188 in radiotherapy application Hyaluronic Acid as vector for liver neoplasies and DNA damage induced by 188Re in vitro systems 110
The challenges of lupus anticoagulants 110
Identifying novel thrombin interactions: Alpha-synuclein binds to thrombin exosites and inhibits thrombin-mediated platelet aggregation 107
Risk-based secondary prevention of obstetric antiphospholipid syndrome. 104
Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study 91
Radiopharmacokinetic and dosimetric studies of 188Re-HA: comparation with 188Re-HHD/lipiodol 88
Effect of anti beta2-glycoprotein I Lupus Anticoagulant antibodies on clotting time in the presence of human umbilical vein endothelial cells 74
Novel thrombin interactions: alpha-synuclein binds thrombin exosites and inhibits thrombin-mediated platelet aggregation 70
Totale 8.116
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.751
article - articoli 23.906
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.657
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021427 0 0 0 0 15 54 35 50 86 38 41 108
2021/2022775 19 95 102 71 13 47 36 86 30 13 73 190
2022/2023642 129 83 10 73 106 78 0 52 67 7 28 9
2023/2024340 4 59 38 19 27 65 24 51 7 1 27 18
2024/20251.260 8 69 79 52 164 38 108 116 90 35 194 307
2025/20262.412 224 424 575 730 459 0 0 0 0 0 0 0
Totale 8.116